RNA Analysis Market

Global RNA Analysis Market Size (2024 to 2029)

The global RNA analysis market size is forecasted to be worth USD 6.92 billion by 2029 from USD 3.61 billion in 2024, growing at a CAGR of 13.9% from 2024 to 2029.

Current Scenario of the Global RNA Analysis Market

Transcriptomics/RNA analysis is the study of the transcriptome, or the entire collection of RNA transcripts generated by the genome, under specific conditions, in each environment, or a given cell, utilizing high-throughput technologies such as microarray analysis. RNA sequencing (RNAseq) is a widely used method for determining gene expression levels. It's a flexible approach for detecting and characterizing gene expression, mutations, gene fusions, and noncoding RNAs, among other things. The fundamental tenet of molecular biology states that information is stored in genes as DNA, then translated into RNA, and finally into proteins. The transcriptome contains several coding and noncoding RNA species and is highly complicated.Targeted RNA sequencing is a precise approach for identifying and sequencing individual transcripts of interest, providing quantitative and qualitative data. The paper's authors used primary and secondary research, including information from various producers and experts. Authors have also concluded that Porter's five force model may assist in making a profit in the sector and taking critical business initiatives to outperform competitors. In a single amplification procedure, targeted RNA sequencing permits the measurement of messenger RNA (mRNA) or targeted noncoding RNA (ncRNA) levels for up to 300 customer-defined genes. Next-generation sequencing techniques have been transformed by the ability to target a specific region of the genome. Exome analysis has increased, with bespoke panels for exome-style pull-down being utilized to evaluate thousands of samples significantly and amplicon analysis, allowing these samples to be run in a single experiment.

MARKET DRIVERS

The global RNA Sequencing analysis market is expected to be driven by the increasing need for personalized medicine and the burgeoning uses of RNA sequencing in the transcriptomics industry.

The primary factor driving the market is the capability of RNA sequencing of high-throughput sequencing methods since this precious benefit provides complete information about a cell's transcriptome. In addition, it offers much greater coverage and higher resolution of the dynamic nature than previous Sanger sequencing and microarray-based methods. Beyond this, RNA-Sequencing also facilitates the researchers in discovering new transcripts, detecting allele-specific expression, and identifying alternatively spliced genes along with quantifying gene expression. Also, the market is predicted to develop due to the rising demand for personalized treatment and RNA sequencing in transcriptomics. Due to the rapid improvements in the transcriptomics sector, the RNA analysis/transcriptomics market is expected to increase significantly throughout the forecast period. Furthermore, the growing focus on biomarker development and toxicogenomic and the growing interest in outsourcing services will likely provide substantial potential prospects for the global RNA analysis/transcriptomics market participants.

Recent advances in the RNA-Sequencing workflow through high-throughput next-generation sequencing have clear advantages over previous approaches since it has revolutionized the dynamic nature of the transcriptome, which has further elucidated the functional complexity of transcription through complementary DNA (cDNA) sequencing. In addition, this technological development has eliminated many of the challenges posed by hybridization-based microarrays, some of which are; the higher sensitivity for genes expressed at a low or very high level, fewer technical variations, the higher dynamic range of expression levels at which transcripts can be detected, higher levels of reproducibility, performed in species even in the absence of genomes, provides unprecedented detail on transcriptional features and being unbiased, unlike other cross-hybridization biased microarrays. Other advantages include detecting new transcripts, a more comprehensive dynamic range, higher specificity and sensitivity, and simple detection of rare and scanty transcripts.The remarkable increase in private and non-private investments may create a fantastic potential for the RNA analysis/transcriptomics market over the forecast period.The growing interest in outsourcing services and the increased focus on biomarker discovery and toxicogenomics will likely provide considerable growth possibilities for worldwide market participants. In addition, the rising rates of genetic mutations in genetic variants and carcinogens are enticing the RNA analysis/transcriptomics market to expand rapidly. Moreover, increasing pharmaceutical and biotechnology R&D expenditure and government funding for omics will likely encourage market growth.

MARKET RESTRAINTS

On the other hand, the high capital investment requirements and data management concerns are projected to limit this market's growth to some extent. Furthermore, high research investment, high failure rates, and challenges with medication delivery are all problems limiting the market's growth for firms in this industry. Nevertheless, RNA-based therapeutics have the potential to flourish despite the limitations, owing to the biotechnology and pharmaceutical sectors' growing interest.

Impact Of Covid-19 On The Global Rna Analysis Market

Due to attempts to better understand the mechanics of the virus, the COVID-19 epidemic has stimulated scientific activities. We predict that the use of transcriptome technologies and personalized medicine will expand at a steady rate over the next five years. Because of the increased research activity, the availability of research money and the demand for high-throughput technology are expected to expand. With an unprecedented demand for the study and treatment of COVID-19, SARS-CoV-2 has brought the RNA sequencing business to the center of attention. The demand for the healthcare system is increasing as the number of instances of COVID-19 rises dramatically worldwide. To decipher the genetic information of SARS-CoV-2, clinicians and scientists are utilizing RNA sequencing in large numbers.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global RNA Analysis Market Analysis By Type

Based on the type, the microarray segment holds the largest market share as it is used to find gene-related diseases. The rising chronic diseases and inborn genetic diseases are accelerating the segment's growth. Microarray instrument demand is increasing because of the rising advances in drug manufacturing technologies. Also, the demand for personalized medicine is expected to raise the market share of microarray instruments. The microarray software segment is growing at a higher pace because of the rising advancements in software development.RNAi Gene Silencing or RNA interference Gene Silencing is anticipated to hold a significant market share over the forecast period since it has become an essential key tool in drug discovery and research from the time of its discovery by Andrew Fire and Craig Mello. Because it allows sequence-specific deletion of target genes, the subsequent phenotypic analysis can be represented by a simple method to assign functions to genes. This not only makes a powerful tool for answering many questions in cell biology but also provides high gene silencing efficiency, stable and long-term silencing by shRNA expression, and easy targeting of the gene of interest.

Global RNA Analysis Market Analysis By Application

Based on the application, the drug discovery segment holds a significant share in the RNA analysis market during the forecast period, followed by toxic genomics owing to the rising population diagnosed with various diseases and growing laboratory practices. As a powerful method to study drug-induced changes in gene expression, RNA-Seq can assess the overall transcriptional effects of a drug throughout the genome, detect fusion genes, and significantly speed up the drug target identification process.The clinical diagnosis segment is expected to rise at a healthy CAGR in the forecast period due to the rise in research on microorganisms and the antibody's information collection. Also, the activities related to genes and proteins are expected to rise. For example, RNA-seq data identifies outlier spliced genes, identifies outliers in gene expression, and detects allele-specific expression, showing an average of 15% diagnostic improvement among eight studies done on RNA‐seq.

Global RNA Analysis Market Analysis By End User

Based on the end-user, the pharmaceutical and biotechnology companies segment is expected to register a significant share in the global market during the forecast period, followed by the hospitals and diagnostics centers due to the mounting diseases and demand for the drugs. In addition, academic researchers and government institutes are using this technology to fulfill the demand. Therefore, the rising prevalence of DNA& RNA technologies will keep this segment at a high pace.

REGIONAL ANALYSIS

The market is covered by Europe, North America, Latin America, the Middle East, and Africa. The primary market is captured by North America, followed by Europe Increasing support by the governments and increasing awareness of the products are prominent factors for the market growth in these countries. In addition, rising incidences of chronic diseases are also greatly influencing the demand of the market.

Asia Pacific region is expected to have higher growth in the forecast period due to increased spending from major countries like India and China for RNA sequencing on research and development.  

KEY PLAYERS IN THE GLOBAL RNA ANALYSIS MARKET

Some of the notable companies operating in the global RNA analysis market profiled in the report are Illumina Inc. (U.S.), Qiagen N.V. (Germany), Affymetrix Inc. (U.S.), Agilent Technologies Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Sigma Aldrich (U.S.), Fluidigm Corporation (U.S.), Bio-Rad Laboratories Inc. (U.S.), G.E. Healthcare (U.S.) and Thermofisher Scientific Inc. (U.S.).

RECENT HAPPENINGS IN THE MARKET

• In October 2022, Oxford Nanopore Technologies launched the world's most affordable high-throughput sequencing device, PromethION 2, or P2 Solo Sequencer, with the potential to dramatically expand access to affordable, accurate, and fast sequencing for human genetics and other variety of larger datasets.

• As of November 2022, DelveInsight released the RNA Interference Competitive Landscape - 2022 report, which provides data on the RNA interference clinical trial pipeline, for which more than 85 key companies are working continuously to develop more than 100 RNA interference therapies.

• In October 2022, Fluent BioSciences showcased its new single-cell RNA sequencing solution PIPseq, which would help any researcher to efficiently perform a wide range of single-cell transcriptomic applications in a single reaction, allowing researchers to set up their experiments without any limitations.

This research report on the global RNA analysis market has been segmented and sub-segmented into the following categories.

By Type

• Microarrays
• Reagents
• Instruments
• Software
• Polymerase Chain Reaction (PCR)
• Sequencing Technologies
• RNAi Gene Silencing

By Application

• Clinical Diagnosis
• Drug Discovery
• Toxic genomics

By End User

• Academic Research & Government Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic Centres

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa